In the rapidly expanding world of wellness influencers and social media trends, distinguishing between legitimate nutritional science and “pseudoscience” is becoming increasingly difficult. Two substances currently occupying significant digital headspace are creatine, a well-documented performance enhancer, and methylene blue, a synthetic dye being marketed as a cognitive booster.
While both are frequently discussed in the same breath, science suggests they belong to entirely different categories of efficacy and safety.
Creatine: The “Backup Battery” for Human Cells
Unlike many supplements that rely on anecdotal claims, creatine is backed by decades of rigorous research, including randomized controlled trials—the gold standard of scientific evidence.
How it works:
Creatine is a naturally occurring compound that helps maintain energy levels within our cells. It functions similarly to a backup battery for adenosine triphosphate (ATP), the body’s primary energy source. When the body undergoes intense physical activity, it consumes ATP rapidly. Creatine is converted into phosphocreatine, which helps replenish ATP levels almost instantly.
Proven benefits include:
– Athletic Performance: Enhances strength, power, and explosive movement in high-performance athletes.
– Muscle Maintenance: Helps aging adults maintain muscle mass, which is a critical factor for long-term longevity.
– Recovery and Protection: May aid in injury prevention and rehabilitation.
– Potential Cognitive Support: Some research suggests it may protect the brain during periods of low blood flow (ischemia), such as during a stroke or concussion, though more human studies are needed to confirm this.
The fine print on creatine:
To see results, experts note that users should stick to pure creatine monohydrate in powder form; other variations lack scientific verification. Furthermore, despite common social media myths regarding muscle cramping, a massive review of 685 clinical trials involving 26,000 people found no significant increased risk of such side effects.
Methylene Blue: High Potential, Low Proof
While creatine is a staple of evidence-based nutrition, methylene blue is a much more controversial subject. A synthetic dye used since the 1870s, it has legitimate medical applications, such as treating methemoglobinemia (a rare blood disorder) and fighting malaria parasites.
However, its sudden popularity as a “nootropic” (a cognitive enhancer) lacks the scientific foundation that creatine enjoys.
The current state of research:
– Animal vs. Human studies: Much of the excitement surrounding methylene blue stems from its potential to treat Alzheimer’s by interacting with tau proteins. However, most of this research has been conducted on animals.
– Lack of clinical evidence: Human trials are currently too small and have shown only negligible effects. There is no compelling evidence yet that it provides a meaningful cognitive boost to the average healthy person.
– Safety concerns: Methylene blue carries significant risks, particularly for individuals taking antidepressants or certain psychiatric medications, due to potential dangerous drug interactions.
The “Pseudoscience” Trap
The overlap of these two substances in online discourse highlights a growing trend: the “cloaking” of pseudoscience in scientific language. Influencers often bundle proven substances like creatine with unproven ones like methylene blue to create a sense of legitimacy, making it difficult for consumers to discern what is a biological necessity and what is a marketing gimmick.
“They [pseudoscience producers] have learned to cloak themselves in the garb of science. They can sound very seductive, and they’re very adept at misleading people.” — Joe Schwarcz, Director of the Office for Science and Society at McGill University
Conclusion:
While creatine is a scientifically validated tool for physical and potentially cognitive health, methylene blue remains an unproven and potentially risky substance for cognitive enhancement. Consumers should prioritize substances backed by large-scale human clinical trials rather than social media trends.
